Vyome secures exclusive license from Impetis for selective JAK inhibitor programs

The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments

Merck & Google Cloud ink $1 billion AI deal to build “Agentic” pharma future

The collaboration will roll out an “agentic” AI platform across Merck’s research & development, manufacturing, commercial, and corporate operations

India Pharma 2026 underscores policy momentum, innovation push, and self-reliance roadmap

The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness

Merck moves to seal $53-a-share takeover of Terns Pharmaceuticals

The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701

Concord Biotech acquires Celliimune to accelerate DNA-engineered cancer therapies

Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy

Lupin and Gan & Lee enter exclusive licensing deal for novel GLP-1 receptor agonist

Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals

Merck strikes historic deal with Trump admin to lower drug costs for Americans

WuXi Biologics teams up with Qatar Free Zones Authority to launch first Middle East CRDMO Centre

This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region

Eli Lilly pledges $40 million to Indiana University to expand clinical trials

The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy

Merck breaks ground on $3 billion center of excellence for pharma manufacturing in Virginia

The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects